Game-Set-MATCH: Liquid Biopsy Advances to the Next Round
A recent article evaluated the concordance rate between tumor and plasma genotyping for detecting actionable genomic alterations to guide targeted therapy. These results support the utility of liquid biopsy for enrolling patients into genomically guided trials, especially in scenarios in which tissue is unavailable or biopsy is not feasible. See related article by Gouda et al., p. 4299.
Authors
- Alessandro Russo (ORCID: https://orcid.org/0000-0002-3365-1972)
- Paola Muscolino (ORCID: https://orcid.org/0009-0004-6450-5953)
- Christian Diego Rolfo (ORCID: https://orcid.org/0000-0002-7860-8417)
Institutions
- University of Messina (IT)
- Humanitas University (IT)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- University of Catania (IT)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1927
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00